Novavax (NVAX) Notes Payables (2010 - 2022)

Novavax (NVAX) recorded quarterly Notes Payables of $324.9 million in Q4 2022, little changed quarter-over-quarter from $324.5 million in Q3 2022.

Novavax (NVAX) Notes Payables (2010 - 2022) Analysis & Trends

Novavax's Notes Payables history runs 8 years deep, the most recent figure standing at $324.9 million for Q4 2022.

In Q4 2022, Notes Payables changed N/A year-over-year to $324.9 million; the TTM figure through Dec 2022 stood at $324.9 million (changed N/A YoY), while the FY2022 annual figure was $324.9 million, changed N/A from the prior year.
Notes Payables was $324.9 million for Q4 2022 at Novavax, roughly flat from $324.5 million in the prior quarter.
In the past five years, Notes Payables ranged from a high of $324.9 million in Q4 2022 to a low of $323.8 million in Q1 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn
9	Abivax	91.96 Bn	91.96 Bn	-
10	Novavax	1.49 Bn	931.98 Mn	108.82 Mn

Download Data